RUNX1 and acute myeloid leukemia: These results agree with those of previous studies demonstrating the importance of allelic burden in RUNX1 and its relevance to FPD/AML progression [38], suggesting that RUNX1 alterations could impair the PKCα/β signaling pathway, promoting the disease’s appearance.